These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Combined treatment with GH, insulin, and indomethacin alleviates cancer cachexia in a mouse model.
    Author: Chen SZ, Qiu ZG.
    Journal: J Endocrinol; 2011 Feb; 208(2):131-6. PubMed ID: 21106721.
    Abstract:
    Cancer-induced cachexia involves weight loss, catabolic activity, and inflammation. We have evaluated the effects of various treatments (GH, insulin (INS), indomethacin (IND), and all possible combinations) on cancer cachexia in a mouse model. BALB/c mice that were implanted with colon-26 adenocarcinoma developed cachexia in 9 days. Body weight, tumor volume, tumor-free weight, inflammatory cytokines (tumor necrosis factor-α (TNF-α), interleukin 6 (IL6)), and nutritional markers (glucose (Glu), albumin, triglycerides (TGs)) of treatment and control groups were monitored. In the cachexia group, there was a significant decrease in tumor-free bodyweight by day 11. Treatment with GH+INS+IND significantly alleviated tumor-free bodyweight reduction and cachexia-induced changes in nutritional markers and cytokines, and prolonged survival time. GH+INS+IND treatment was more effective than other treatment combinations in elevating Glu and TGs, reducing TNF-α and IL6 levels, and prolonging survival time. In conclusion, GH+INS+IND alleviated cachexia symptoms in a murine model of cancer cachexia.
    [Abstract] [Full Text] [Related] [New Search]